Antigen‐specific TIL therapy for melanoma: A flexible platform for personalized cancer immunotherapy
Sander Kelderman(The Netherlands Cancer Institute), Nina Schumacher(The Netherlands Cancer Institute), Marit M. van Buuren(The Netherlands Cancer Institute), John B.A.G. Haanen(B. J. Medical College & Sassoon Hospital), Mireille Toebes(The Netherlands Cancer Institute), Bianca Heemskerk(The Netherlands Cancer Institute), Lorenzo F. Fanchi(The Netherlands Cancer Institute), Nienke van Rooij(The Netherlands Cancer Institute), Lothar Germeroth, Daisy Philips(The Netherlands Cancer Institute), Samira Michels(The Netherlands Cancer Institute), Pia Kvistborg(The Netherlands Cancer Institute)
Cited by 41
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
|The Lancet Oncology|2014|978
Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma
|Journal of Clinical Oncology|2013|799